This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

PFS (LUX-Lung 7 clinical data)
XOVOLTIB® significantly improved PFS versus gefitinib1

LUX-Lung 7: PFS by independent review (coprimary endpoint)

  • 27% reduction in relative risk of disease progression versus gefitinib (HR=0.73; 95% CI, 0.57–0.95; P=0.017)1
  • Patients were twice as likely to be alive and progression-free at 2 years versus gefitinib1
  • PFS benefit consistent across subgroups, including EGFR mutation type1

ORR (LUX-Lung 7 clinical data)
XOVOLTIB® significantly improved response rates versus gefitinib in patients with both del19 and L858R1

  • Improved ORR and disease control rates versus gefitinib (ORR: 70% vs 56%; P=0.0083)1
  • Longer duration of response versus gefitinib (10.1 vs 8.4 months, respectively)1

ORR=objective response rate; PFS=progression-free survival; TTF=time to treatment failure.

TTF (LUX-Lung 7 clinical data)
Patients remained on treatment with XOVOLTIB® significantly longer than with gefitinib1

LUX-Lung 7: Time to treatment failure (coprimary endpoint)

  • XOVOLTIB® significantly extended TTF versus gefitinib1
  • TTF chosen to reflect real-world clinical practice and treatment guidelines; ~30% of patients continued on treatment with TKIs beyond radiological progression in the absence of clinical deterioration1
  • 27% significant reduction in relative risk of treatment failure versus gefitinib (P=0.0073)1

CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; PFS=progression-free survival.

You may be interested in: 

Is this information compelling to you?

References

  1. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top